New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:46 EDTEWEdwards Lifesciences a takeover candidate, says Canaccord
Canaccord believes the unexpected simultaneous approval of Edwards Lifesciences' SAPIEN XT heart valve and its green light for XT to treat high risk patients with severe aortic stenosis will cause Street estimates to increase. The firm views Edwards as an attractive acquisition candidate, citing its focus on a large and growing market and its high operating margins, and has a Buy rating with a $96 price target on the stock.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
10:13 EDTEWHigh option volume stocks
Subscribe for More Information
06:34 EDTEWEdwards Lifesciences price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
September 18, 2014
09:19 EDTEWGeneration Investment reports 5.2% passive stake in Edwards Lifesciences

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use